Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.59 |
| ▸ | APP | P05067 | 2/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 7/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MPL | P40238 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28663078 | 0.87 | KIF11 (0.42) | KIF11APPAKR1C3AKR1C2FEN1 | |
| SCHEMBL5851644 | 0.85 | KIF11 (0.63) | KIF11APPTSHRGLAPOLB | |
| SCHEMBL3784912 | 0.84 | PDE3B (0.46) | KIF11FEN1ALOX5APTSHRGLA | |
| SCHEMBL6011433 | 0.83 | KIF11 (0.61) | KIF11APPFEN1TSHRGLA | |
| SCHEMBL24031277 | 0.83 | RORC (0.56) | APPFEN1ALOX5APRORC | |
| SCHEMBL13385864 | 0.82 | KIF11 (0.46) | KIF11APPAKR1C3AKR1C2FEN1 | |
| Water SCHEMBL28611987 | 0.82 | PDE3B (0.45) | KIF11FEN1ALOX5APTSHRGLA | |
| SCHEMBL5685519 | 0.81 | KIF11 (0.59) | KIF11APPFEN1ALOX5APTSHR | |
| Hydrochloric Acid SCHEMBL6011297 | 0.81 | KIF11 (0.59) | KIF11APPFEN1TSHRGLA | |
| SCHEMBL4659904 | 0.81 | TSHR (0.68) | KIF11APPFEN1ALOX5APTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706111-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1694281-A4 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070259951-A1 | Compounds, Compositions and Methods | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070142460-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-06-21 | — | — | US | disclosed |
| EP-1706111-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-04 | — | — | EP | disclosed |
| EP-1694281-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005062847-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005060692-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259951-A1 | Compounds, Compositions and Methods | ALPP, PCNA, MKI67 | KIF11 824/4885APP 4406/4885AKR1C3 1014/4885 |
| US-20070142460-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885APP 4406/4885AKR1C3 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.